CD8A and neoplasm: Cancer vaccine takes advantage of tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs) to stimulate the immune system, especially a robust and long-lasting immune response of CD8+ T cells to inhibit the growth, metastasis, and recurrence of tumor cells [60].